



Investor Presentation

February 2025

Disclaimers

Forward-Looking Statements


This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our future results of operations and financial position, including the underlying assumptions of any such projections, industry and business trends, our prospective value to constituents, our collaborations and partnerships with third parties, including our integrated savings programs, our hybrid contracting model with PBMs and select pharmacies, our business strategy, our plans, our market opportunity and growth, our executive officer transitions, the impacts of PBM regulation and reform on our business and our objectives for future operations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward looking statements, including, but not limited to, risks related to our limited operating history and early stage of growth; our ability to achieve broad market education and change consumer purchasing habits; our general ability to continue to attract, acquire and retain consumers, in a cost-effective manner; our reliance on our prescription transactions offering and ability to expand our offerings; changes in medication pricing and pricing structures; our general inability to control the categories and types of prescriptions for which we can offer savings or discounted prices; our reliance on a limited number of industry participants, including pharmacy benefit managers, pharmacies, and pharma manufacturers; the competitive nature of industry; risks related to pandemics, epidemics or outbreak of infectious disease; the accuracy of our estimate of our total addressable market and other operational metrics; our ability to respond to changes in the market for prescription pricing and to maintain and expand the use of GoodRx codes; our ability to maintain positive perception of our platform and brand; risks related to any failure to maintain effective internal control over financial reporting; risks related to use of social media, emails, text messages and other messaging channels as part of our marketing strategy; our dependence on our information technology systems and those of our third-party vendors, and risks related to any failure or significant disruptions thereof; risks related to government regulation of the internet, e-commerce, consumer data and privacy, information technology and cybersecurity; risks related to a decrease in consumer willingness to receive correspondence or any technical, legal or any other restrictions to send such correspondence; risks related to any failure to comply with applicable data protection, privacy and security, advertising and consumer protection laws, standards, and other requirements; our ability to utilize our net operating loss carryforwards and certain other tax attributes; the risk that we may not achieve the intended outcomes of our restructuring and cost reduction efforts; our ability to attract, develop, motivate and retain well-qualified employees; risks related to our acquisition strategy; risks related to our debt arrangements; interruptions or delays in service on our apps or websites; our reliance on third-party platforms to distribute our platform and offerings, including software as-a-service technologies; systems failures or other disruptions in the operations of these parties on which we depend; risks related to climate change; the increasing focus on environmental sustainability and social initiatives; risks related to our intellectual property; risks related to operating in the healthcare industry; risks related to our organizational structure; litigation related risks; our ability to accurately forecast revenue and appropriately plan our expenses in the future; risks related to general economic factors, natural disasters or other unexpected events; risks related to fluctuations in our tax obligations and effective income tax rate which could materially and adversely affect our results of operations; risks related to the recent healthcare reform legislation and other changes in the healthcare industry and in healthcare spending which may adversely affect our business, financial condition and results of operations; as well as the other important factors discussed in the section entitled "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2024, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. The forward-looking statements in this presentation are based upon information available to us as of the date of this presentation, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Industry, Market and Other Data

This presentation contains estimates, projections and information concerning our industry, our business and the market size and growth rates of the markets in which we participate. Some data and statistical and other information are based on independent reports from third parties, as well as industry and general publications and research, surveys and studies conducted by third parties which we have not independently verified. Some data and statistical and other information are based on internal estimates and calculations that are derived from publicly available information, research we conducted, internal surveys, our management's knowledge of our industry and their assumptions based on such information and knowledge, which we believe to be reasonable. In each case, this information and data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such information, estimates or projections. Industry publications and other reports we have obtained from independent parties may state that the data contained in these publications or other reports have been obtained in good faith or from sources considered to be reliable, but they do not guarantee the accuracy or completeness of such data. In addition, projections, assumptions and estimates of the future performance of the industry in which we operate and our future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the sections titled "Forward-Looking Statements" and "Risk Factors" included in our filings with the SEC. These and other factors could cause our future performance to differ materially from the assumptions and estimates made by third parties and us.

Certain statements, findings, conclusions, views, and opinions contained and expressed in this presentation are based in part on data obtained under license from the following non-exhaustive list of information services: Utilization Management Report, OPC Report, Market Share Library Report, 2018 – 2024, IQVIA Inc. All Rights Reserved. The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IQVIA Inc. or any of its affiliated or subsidiary entities. Any analysis is independently arrived at by us, on the basis of the data and other information.

The cost of healthcare in the U.S. continues to increase & Americans are bearing the burden



Premiums, deductibles and copays are rising¹


Health insurance plan costs are projected to increase 9% in 2025¹, outpacing wage growth²



Drug coverage and formularies are narrowing¹


37% more formulary exclusions in 2022 vs 2020³

Over 17 million people disenrolled from Medicaid⁴



GoodRx offers real savings and is uniquely positioned as a complement to insurance


1. Based on Aon's U.S. Employer Health Care Costs report published in August 2024.
2. Based on the Bureau of Labor Statistics' employment cost index report published in December 2023.
3. Based on Fein, Adam J., The 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers, Drug Channels Institute, 2024. Drug Channels Institute analysis of Xcenda data.
4. Based on KFF Analysis of State Unwinding Dashboards and Monthly Reports to CMS, as of March 2024.



Our mission is to help Americans get the healthcare they need at a price they can afford.

Believe market opportunity is substantial with significant room for growth

GoodRx represents only ~2% of all Rx's filled in the US annually¹



Over **6 Billion** annual prescriptions⁵

~**1 Billion** annual physician visits⁶

U.S. prescription drug spend is projected to grow ~**5%** per year on average⁷

Consumers visit their pharmacy almost **twice as often** as they visit their physician⁸

Fragmented marketplace

1. Source: IQVIA & GoodRx data; Unadjusted Rx's for 2023.

2. CMS: 2023 National Health Expenditures.

3. Prescription drugs market size based on CMS projected 2024 and 2025 market size + GoodRx estimate regarding unfilled prescriptions.

4. Pharma manufacturer solutions market size based on recent internal data regarding the amount of advertising and marketing spending by U.S. pharma manufacturers relating to prescription drugs in 2022.

5. Source: IQVIA from 1/1/23-12/31/23; Prescription amount has been adjusted to count prescriptions of multi-month supplies on a per month basis (e.g., 90-day fills have been adjusted to count as 3 30-day fills and 60-day fills have been adjusted to count as 2 30-day fills).


6. 2022 Physician Office Market Report.

7. Source: CMS. Growth projection is for years 2022 through 2031.

8. Source: National Library of Medicine. Pharmacists as accessible health care professionals: quantifying the opportunity published January 2022.

Americans use GoodRx to save an average of ~84%¹ on prescriptions compared to retail prices

GoodRx beats the average copay ~50% of the time for our most commonly prescribed medications²



GoodRx Consumers' Top Conditions⁴

- 1 Hypertension
- 2 Depression
- 3 Coronary Artery Disease
- 4 High Cholesterol
- 5 Heart Failure

1. Based on internal data; Average savings for GoodRx users for 2024, comparing the GoodRx discounted price to the usual and customary, or cash price.

2. Based on a GoodRx study, The GoodRx Effect, dated January 2024. In the last twelve months ended September 30, 2023, approximately 50% of the 100 most purchased prescriptions filled using GoodRx (including its membership savings programs) were cheaper than the average commercial insurance stated copays, based on industry data. When GoodRx users paid less than the average commercial insurance copays for these most commonly purchased medications, they saved on average about 50% off average commercial insurance copays.

3. GoodRx Power Patients Survey, n=1,075 Standard Users, n=1,624 Power Patients (weighted), Conducted August 28–September 13, 2023.

4. Top Conditions in 2023 based on GoodRx total claims volume.

GoodRx delivers value to key constituents, starting with consumers and healthcare professionals

Consumers

~\$17B

Consumer savings annually¹

Pharmacies

- Customer acquisition
- Cost-based economics

Payors

- Lower costs for members and plans



Physicians

1M+

Unique HCPs visit GoodRx annually²

PBM³s

- Proven growth channel
- Long-term partnerships

Manufacturers

- Engage and convert high-intent users
- Drive brand awareness

1. Based on 2024 consumer savings. Savings are measured as the difference between the pharmacy list price and the price the consumer pays utilizing a GoodRx code at the same pharmacy.

2. Based on internal data on unique HCP visits to GoodRx for the year ended December 31, 2024. A unique HCP who visits GoodRx more than once during a given year is only counted as one unique HCP in that year.

3. PBM refers to a pharmacy benefit manager. PBMs aggregate demand to negotiate prescription medication prices with pharmacies and pharma manufacturers. PBMs find most of their demand through relationships with insurance companies and employers. However, nearly all PBMs also have consumer direct or cash network pricing that they negotiate with pharmacies for consumers who choose to purchase prescriptions outside of insurance.

A trusted prescription affordability solution

Prescription Marketplace

Aggregates Discounted Prescription Pricing Options Available to Consumers

Pharmacy-Direct Contracting

PBM Contracting

- Consumer savings
- Pharmacy-Direct Contracting is informed by acquisition cost-based pricing¹
- Broad network access

Pharma Manufacturer Solutions

Partner with Pharma to Facilitate Integrated Access Solutions for Brand Medications

Embedded Copay and Patient Support Programs

Point-of-Sale Discount Programs for Brands


- Consumer savings and access
- Pharma awareness and pull through

GoodRx makes the complex simple and powerful for consumers


Data Sources

- Multiple Pharmacy Benefit Manager Networks
- Retail-direct contracts
- Pharmacy savings programs
- Usual & customary prices
- Medicare prices
- Pharmaceutical manufacturers
- Patient assistance programs

Engine



Customized Options



We reach healthcare professionals (HCPs) at the high-intent, point of prescription

Digital tools to communicate savings to patients at the point of prescription, including Electronic Health Record (EHR) integrations

90%

estimated awareness with HCPs¹

80%+



estimated HCPs recommended GoodRx in 2023¹

1M+

unique HCPs visit GoodRx annually²

1.5M+

prescribers have a patient who used GoodRx in 2024³




1. Based on a survey conducted by GoodRx between January 1, 2023 - December 31, 2023.

2. Based on internal data on unique HCP visits to GoodRx for the year ended December 31, 2024. A unique HCP who visits GoodRx more than once during a given year is only counted as one unique HCP in that year.

3. For the year ended 12/31/24.

Hybrid contracting model: Aligning economic incentives with PBMs and pharmacies to help drive sustainable growth

PBM Contracting




-  Expansive network of PBMs³
-  Take rate is a mid-teen percentage of GMV⁴; take rate in dollars = GoodRx revenue
-  GoodRx, Inc. has never had a PBM terminate
-  Higher revenue share with higher volume in many tiered contracts
-  PBMs have fixed cost structures that benefit from incremental volume

Consumers present GoodRx at one of over 70,000 pharmacies (or refill at their preferred pharmacy with stored GoodRx information¹) with GoodRx users having saved an average of 84%+² on retail prices for their prescription medication

1. When a consumer uses GoodRx, their profile is saved at the pharmacy. From then on, GoodRx typically applies to future refills as well as, in many cases, fills for other prescriptions at that location, without the consumer having to re-present their GoodRx information.
 2. Based on internal data; Average savings for GoodRx users in 2024, comparing the GoodRx discounted price to the usual and customary, or cash price.
 3. PBM refers to a pharmacy benefit manager. PBMs aggregate demand to negotiate prescription medication prices with pharmacies and pharma manufacturers. PBMs find most of their demand through relationships with insurance companies and employers. However, nearly all PBMs also have consumer direct or cash network pricing that they negotiate with pharmacies for consumers who choose to purchase prescriptions outside of insurance.
 4. As of Q4 2024. GMV represents gross merchandise value, which is the aggregate price paid by our consumers who used a GoodRx code available through our platform for their prescriptions during such period. GMV excludes any prices paid by consumers linked to our other offerings, including our subscription offerings.

Hybrid contracting model: Aligning economic incentives with PBMs and pharmacies to help drive sustainable growth

Pharmacy-Direct Contracting



Consumers present GoodRx at one of over 70,000 pharmacies (or refill at their preferred pharmacy with stored GoodRx information¹) with GoodRx users having saved an average of 84%+² on retail prices for their prescription medication

-  Hybrid model (combination of PBM³ and retail-direct contracts) took shape as pharmacy margins were compressing and GoodRx was in a unique position to help
-  **We're able to contract directly with retail pharmacies without PBM involvement; Pharmacy payment to GoodRx = revenue**
-  Strengthens retail pharmacy relationships and collaboration on solutions focused on mutual success and profitability
-  Retailer-direct contracts with most of our largest retail pharmacy partners, and our directly contracted medication volume makes up a growing minority of our prescription transactions volume.


1. When a consumer uses GoodRx, their profile is saved at the pharmacy. From then on, GoodRx typically applies to future refills as well as, in many cases, fills for other prescriptions at that location, without the consumer having to re-present their GoodRx information.
2. Based on internal data; Average savings for GoodRx users in 2024, comparing the GoodRx discounted price to the usual and customary, or cash price.
3. PBM refers to a pharmacy benefit manager. PBMs aggregate demand to negotiate prescription medication prices with pharmacies and pharma manufacturers. PBMs find most of their demand through relationships with insurance companies and employers. However, nearly all PBMs also have consumer direct or cash network pricing that they negotiate with pharmacies for consumers who choose to purchase prescriptions outside of insurance.
4. GMV represents gross merchandise value, which is the aggregate price paid by our consumers who used a GoodRx code available through our platform for their prescriptions during such period. GMV excludes any prices paid by consumers linked to our other offerings, including our subscription offerings.

Integrating GoodRx savings with insurance

Our integrated savings program (ISP) automatically compares offerings and routes insured consumers to whichever eligible price is lower for their medication, the GoodRx price¹ or the insurance price, and applies it to their deductible

Programs live with Express Scripts, CVS Caremark, MedImpact, and Navitus²

How our Integrated Savings Program works



- SAM expanding; helps reach members who might not be discount card users
- Partnering with PBMs partners who cover >**60%** of insured lives to aggregate demand for our prescription discounts³
- Levers to drive growth: number of lives and conversion; ISP contributes to prescription transactions revenue

1. The GoodRx price is based on the lowest available price from our network of PBMs for that pharmacy location or the contracted retail-direct price.

2. As of January 2024.

3. Based on 2023 PBM market share data from Drug Channels Institute. As of January 2024, the GoodRx ISP program was available to a subset of PBM partners' eligible members.


Subscription products can deliver more value to consumers & extend our reach focusing on users with chronic conditions

\$20.7M


subscription revenue in 4Q24

684k


subscription plans¹



Prescription Savings



Home Delivery



Discounted Telehealth



GoodRx Gold monthly & annual subscription plan²

- 1,000+ prescriptions under \$10 at up to 90% savings off list prices
- Free mail delivery
- Discounted access to telehealth services

GoodRx partners with pharma manufacturers to help enhance commercial investment and increase LTV

We integrate pharma brand messaging, access solutions, and support services into the GoodRx platform to enable more patients to fill & refill their Rx's



Copay & Patient
Support Programs




Point-of-Sale
Discount Programs

Integrated Access Solutions




Consumer



HCP

Media Solutions

Our brand access and affordability engine delivers strong results that create wins for our partners and patients



Better pricing for drugs where insurance coverage is challenging



Remove consumer and HCP friction for rejects and utilization management



Transactions directly measurable by pharma¹



Attractive pharmacy reimbursement¹

1. Through our point-of-sale discount programs for brands.

We are focused on driving sustainable partnerships and scalable growth with strong ROI



200+

Brands we work with¹



78

Signed point-of-sale discount programs with brands²



65%

Of our users found out about manufacturer savings programs for the first time from GoodRx³

Case Study: HCP Program on GoodRx showed 2.4% lift in NRx in just 3 months⁴

Change in Market Share in Test Period



10% annualized lift
in new treatments vs control



7% increase in Rx's
among the client's high decile HCPs

1. Based on 2024 internal data, across both access and media solutions.
 2. As of December 2024.
 3. Based on internal research and survey conducted from June 2023 to July 2023
 4. Test vs. control measurement study conducted by IQVIA, measurement period October-December 2023

Strengths for us to build on

Powerful Value Proposition

- High HCP & Consumer NPS¹
- Ability to drive ~\$17B of consumer savings annually²
- Scope of PBM and retail networks

Ways to Grow

- Driving even more meaningful prescription savings
- Tighter partnerships with retail pharmacies through hybrid retails contracting model
- Expanding our integrated saving programs with funded benefit plans
- Growing our pharma manufacturer solutions business

Massive Scale + Impact

~30M

consumers used GoodRx for prescription savings in 2024³

1M+

Unique HCPs visited GoodRx in 2024⁴




1. HCP NPS based on survey ran in February 2024; Consumer NPS based on survey ran in January 2024.

2. Based on 2024 consumer savings. Savings are measured as the difference between the pharmacy list price and the price the consumer pays utilizing a GoodRx code at the same pharmacy.

3. For the year ended 12/31/24.

4. For the year ended 12/31/24.


We have disciplined focus against key priorities



Revenue growth with attractive margin profile


Revenue

(dollars in millions)



Adjusted EBITDA & Margin¹

(dollars in millions)



Note: Due to rounding, numbers presented may not add up precisely to the totals provided.

1. Adjusted Revenue, Adjusted EBITDA and Adjusted EBITDA Margin are non-GAAP financial measures and are presented for supplemental informational purposes only. We define Adjusted Revenue for a particular period as revenue excluding client contract termination costs associated with the restructuring related activities. We exclude these costs from revenue because we believe they are not indicative of past or future underlying performance of the business. For all periods other than Q3 2023, revenue equals or is expected to equal Adjusted Revenue. Refer to Appendix for reconciliation of Adjusted Revenue, Adjusted EBITDA and Adjusted EBITDA Margin to the most directly comparable GAAP measures.

2. Revenue excluding the \$10.0 million client contract termination payment represents Adjusted Revenue for the third quarter 2023. For all other periods, revenue equals Adjusted Revenue.

Our management team is mission-driven and committed to improving healthcare in America

Strong leadership team with an advantaged mix of experienced executives from adjacent industries



Wendy Barnes
CEO and President



Chris McGinnis
Chief Financial Officer



Trevor Bezdek
Co-Founder & Co-Chairman



Aaron Crittenden
Interim SVP, Rx Marketplace



Dorothy Gemmell
Chief Commercial Officer



Nitin Shingate
Chief Technology Officer



Vina Leite
Chief People Officer



Ryan Sullivan
Chief Marketing Officer



Grayce Cheng
SVP & General Counsel



Romin Nabiey
Chief Accounting Officer



Building the leading digital platform for consumer healthcare in the U.S.



Unique combination of **scale, impact, and profitability**¹



Macro trends drive the need for our solutions and technology



First mover advantage and partnership strategy help **deepen the competitive moat**



Transparency and **trust** are core to our platform



Consumer first approach



Powerful **value proposition**

Appendix

GoodRx at a glance: Strengthening our ecosystem while driving profitable growth

Scaled Platform

7M+

Prescription-related Consumers²

1M+

Unique HCPs visit GoodRx annually⁶

360B+

Daily pricing data points distilled into real-time data⁹

Consumer First

~30M

Consumers used GoodRx for prescription savings in 2024³

\$85B+

Cumulative Consumer Savings⁷

84%+

Average saved off retail prices by GoodRx users¹⁰

Trusted Ecosystem Partner

8 / 10

Of our top pharmacies directly contracted with us⁴

1.5M+

Prescribers with a patient who has used GoodRx in 2024⁸

70K+

U.S. pharmacies accept GoodRx

Profitable¹ Growth

\$792.3M / 6%

2024 Revenue

YOY growth

\$260.2M / 32.8%

2024 AEBITDA⁵

AEBITDA Margin⁵

80%+

Repeat Activity¹¹

1. On an Adjusted EBITDA basis. Adjusted EBITDA is a non-GAAP financial measure and is presented for supplemental information purposes only. Refer to Appendix for reconciliation to the most directly comparable GAAP measure.

2. Represents sum of Monthly Active Consumers for Q3 2024 and subscribers to our subscription plans as of December 31, 2024.

3. For the year ended 12/31/24.

4. As of 12/31/24. Includes pharmacies having either a fully direct contract or hybrid contract model with GoodRx.

5. Adjusted EBITDA and Adjusted EBITDA Margin are non-GAAP financial measures. Refer to Appendix for reconciliation of Adjusted EBITDA and Adjusted EBITDA Margin to the most directly comparable GAAP measures.

6. Based on internal data on unique HCP visits to GoodRx for the year ended December 31, 2024. A unique HCP who visits GoodRx more than once during a given year is only counted as one unique HCP in that year.

7. As of December 2024. Savings are measured as the difference between the pharmacy list price and the price the consumer pays utilizing a GoodRx code at the same pharmacy. Because consumers of our website and mobile application may switch pharmacies if they find a better discount, our consumer savings calculation includes an estimate of savings achieved based on switching pharmacies.


8. Based on internal data as of 12/31/24.

9. Based on internal data as of February 2025.

10. Based on internal data; Average savings for GoodRx users in 2024 comparing the GoodRx discounted price to the usual and customary, or cash price.

11. Based on 2023 internal data. Repeat activity refers to the second and later use of our discounted prices by a single GoodRx consumer.

Our network strengthens with every transaction



Definitions

Hybrid Contracting Model – Refers to a 4 prong strategy:

1. **Traditional PBM network:** Multiple PBM price points for one pharmacy
2. **Single source PBM opportunity:** One PBM network on behalf of one singular pharmacy
3. **True hybrid model:** Still rely on PBM to contract most of the network, but we directly contract with pharmacy on a subset of drugs
4. **Full direct contracting model:** Our pricing relationship with that pharmacy is between us and them, no PBM involvement

MACs (Monthly Active Consumers) – Refers to the number of unique consumers who have used a GoodRx code to purchase a prescription medication in a given calendar month and have saved money compared to the list price of the medication. A unique consumer who uses a GoodRx code more than once in a calendar month to purchase prescription medications is only counted as one Monthly Active Consumer in that month. A unique consumer who uses a GoodRx code in two or three calendar months within a quarter will be counted as a Monthly Active Consumer in each such month. Monthly Active Consumers do not include subscribers to our subscription offerings, consumers of our pharma manufacturer solutions offering, or consumers who used our telehealth offering. When presented for a period longer than a month, Monthly Active Consumers are averaged over the number of calendar months in such period.

GMV (Gross Merchandise Value) – The aggregate price paid by our consumers who used a GoodRx code available through our platform for their prescriptions during such period. GMV excludes any prices paid by consumers linked to our other offerings, including our subscription offerings.

HCPs – Healthcare professionals.

ISP – Integrated savings program.

NPS – Net promoter score.

Partner Pharmacies – Select licensed pharmacies with whom we have direct contractual agreements.

PBMs (Pharmacy Benefit Managers) – PBMs aggregate demand to negotiate prescription medication prices with pharmacies and pharma manufacturers. PBMs find most of their demand through relationships with insurance companies and employers. However, nearly all PBMs also have consumer direct or cash network pricing that they negotiate with pharmacies for consumers who choose to purchase prescriptions outside of insurance.

Prescribers – Refers to individuals in the medical profession who are allowed to write orders for medical treatment.

Subscription Plans – Represent the ending subscription plan balance across both of our subscription offerings, GoodRx Gold and Kroger Savings Club (which sunset in July 2024). Each subscription plan may represent more than one subscriber since family subscription plans may include multiple members.

Savings, Saved, or other similar references – Refers to the difference between the list price for a particular prescription at a particular pharmacy and the price paid by the GoodRx consumer for that prescription utilizing a GoodRx code available through our platform at that same pharmacy. In certain circumstances, we may show a list price on our platform when such list price is lower than the negotiated price available using a GoodRx code and, in certain circumstances, a consumer may use a GoodRx code and pay the list price at a pharmacy if such list price is lower than the negotiated price available using a GoodRx code. We do not earn revenue from such transactions, but our savings calculation includes an estimate of the savings achieved by the consumer because our platform has directed the consumer to the pharmacy with the low list price. This estimate of savings when the consumer pays the list price is based on internal data and is calculated as the difference between the average list price across all pharmacies where GoodRx consumers paid the list price and the average list price paid by consumers in the pharmacies to which we directed them. We do not calculate savings based on insurance prices as we do not have information about a consumer's specific coverage or price. We do not believe savings are representative or indicative of our revenue or results of operations.

Non-GAAP Financial Measures

The following table presents a reconciliation of net (loss) income and revenue, the most directly comparable financial measures calculated in accordance with GAAP, to Adjusted EBITDA and Adjusted Revenue, respectively, and presents net (loss) income margin, the most directly comparable financial measure calculated in accordance with GAAP, with Adjusted EBITDA Margin:

(dollars in thousands)

	Three Months Ended March 31,		Three Months Ended June 30,		Three Months Ended September 30,		Three Months Ended December 31,		Year Ended December 31,	
	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023
Net (loss) income	\$ (1,009)	\$ (3,290)	\$ 6,694	\$ 58,786	\$ 3,965	\$ (38,495)	\$ 6,740	\$ (25,869)	\$ 16,390	\$ (8,868)
Adjusted to exclude the following:										
Interest income	(7,555)	(7,234)	(6,334)	(7,814)	(4,797)	(8,649)	(4,587)	(8,474)	(23,273)	(32,171)
Interest expense	14,643	13,133	14,566	14,054	12,355	14,720	11,358	14,821	52,922	56,728
Income tax expense (benefit)	1,302	6,886	4,952	(46,718)	4,147	(8,106)	4,669	1,234	15,070	(46,704)
Depreciation and amortization	15,942	14,939	16,965	16,097	17,535	33,024	19,096	43,608	69,538	107,668
Other expense	—	1,808	—	—	2,660	2,200	—	—	2,660	4,008
Loss on extinguishment of debt	—	—	—	—	2,077	—	—	—	2,077	—
Financing related expenses	440	—	392	—	66	—	—	—	898	—
Acquisition related expenses	174	1,056	174	385	65	162	144	174	557	1,777
Restructuring related expenses	(125)	—	566	—	—	22,389	8,461	4,634	8,902	27,023
Legal settlement expenses	13,000	—	—	—	—	3,000	—	(2,900)	13,000	100
Stock-based compensation expense	25,096	25,499	26,590	17,897	26,381	32,646	20,959	28,778	99,026	104,820
Payroll tax expense related to stock-based compensation	879	440	847	405	510	580	235	268	2,471	1,693
Loss on operating lease assets	—	—	—	374	—	—	—	979	—	1,353
Adjusted EBITDA	\$ 62,787	\$ 53,237	\$ 65,412	\$ 53,466	\$ 64,964	\$ 53,471	\$ 67,075	\$ 57,253	\$ 260,238	\$ 217,427
Revenue	\$ 197,880	\$ 183,986	\$ 200,610	\$ 189,677	\$ 195,251	\$ 179,958	\$ 198,583	\$ 196,644	\$ 792,324	\$ 750,265
Adjusted to exclude the following:										
Client contract termination costs	—	—	—	—	—	10,000	—	—	—	10,000
Adjusted Revenue	\$ 197,880	\$ 183,986	\$ 200,610	\$ 189,677	\$ 195,251	\$ 189,958	\$ 198,583	\$ 196,644	\$ 792,324	\$ 760,265
Net (loss) income margin	(0.5%)	(1.8%)	3.3%	31.0%	2.0%	(21.4%)	3.4%	(13.2%)	2.1%	(1.2%)
Adjusted EBITDA Margin	31.7%	28.9%	32.6%	28.2%	33.3%	28.1%	33.8%	29.1%	32.8%	28.6%